CA2358094A1 - Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 - Google Patents

Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 Download PDF

Info

Publication number
CA2358094A1
CA2358094A1 CA002358094A CA2358094A CA2358094A1 CA 2358094 A1 CA2358094 A1 CA 2358094A1 CA 002358094 A CA002358094 A CA 002358094A CA 2358094 A CA2358094 A CA 2358094A CA 2358094 A1 CA2358094 A1 CA 2358094A1
Authority
CA
Canada
Prior art keywords
cell
polynucleotide
aav
promoter
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002358094A
Other languages
English (en)
French (fr)
Inventor
Shangzhen Zhou
Varavani Dwarki
Keyun Qing
Cathryn Mah
Arun Srivastava
Jonathan Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of CA2358094A1 publication Critical patent/CA2358094A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
CA002358094A 1998-12-31 1999-12-29 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 Abandoned CA2358094A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11459698P 1998-12-31 1998-12-31
US60/114,596 1998-12-31
PCT/US1999/031220 WO2000039311A1 (en) 1998-12-31 1999-12-29 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2

Publications (1)

Publication Number Publication Date
CA2358094A1 true CA2358094A1 (en) 2000-07-06

Family

ID=22356219

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002358094A Abandoned CA2358094A1 (en) 1998-12-31 1999-12-29 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2

Country Status (5)

Country Link
EP (1) EP1141339A4 (de)
JP (1) JP2002533128A (de)
AU (1) AU2596400A (de)
CA (1) CA2358094A1 (de)
WO (1) WO2000039311A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4552700A (en) * 1999-04-19 2000-11-02 Ballermann, Barbara Jutta Gene therapy
DK1469878T3 (da) 2002-01-31 2011-07-18 Max Planck Gesellschaft FGFR agonister
EP1332761A1 (de) * 2002-01-31 2003-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Agoniste von Fibroblasten-Wachstumsfaktorrezeptoren
AU2010223888A1 (en) * 2009-03-13 2011-10-06 Egen, Inc. Compositions and methods for the delivery of biologically active RNAs
US8808684B2 (en) 2010-09-10 2014-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction
CN116688095B (zh) * 2023-03-08 2024-09-10 中国人民解放军海军军医大学 受体酪氨酸激酶fgfr1的抗疱疹病毒作用及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5486599A (en) * 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
WO1992000999A1 (en) * 1990-07-06 1992-01-23 Rhone-Poulenc Rorer International (Holdings) Inc. Fibroblast growth factor receptors
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
AU4344197A (en) * 1996-09-13 1998-04-02 Albert Einstein College Of Medicine Of Yeshiva University Car, a novel coxsackievirus and adenovirus receptor
WO1999011652A1 (en) * 1997-09-02 1999-03-11 Advanced Research And Technology Institute Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression

Also Published As

Publication number Publication date
JP2002533128A (ja) 2002-10-08
EP1141339A1 (de) 2001-10-10
AU2596400A (en) 2000-07-31
EP1141339A4 (de) 2002-04-17
WO2000039311A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
US11766448B2 (en) Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer
US7244617B2 (en) Diminishing viral gene expression by promoter replacement
US8278428B2 (en) Mitochondrial nucleic acid delivery systems
JPH06504680A (ja) 遺伝子療法のための安全ベクター
Zaiss et al. Hepatocyte heparan sulfate is required for adeno-associated virus 2 but dispensable for adenovirus 5 liver transduction in vivo
US20240252684A1 (en) Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
WO1999018227A1 (en) Chimeric parvovirus-based recombinant vector system that specifically targets the erythroid lineage
JP2002506651A (ja) 多重遺伝子ベクター
CA2358094A1 (en) Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
US7052692B1 (en) Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
US6517828B1 (en) C-CAM as an angiogenesis inhibitor
WO1999064569A1 (en) Methods and compositions for generating recombinant adeno-associated virus vectors
US7405284B2 (en) Reducing cellular dysfunction caused by mitochondrial gene mutations
US20230405151A1 (en) Use of irak4 modulators for gene therapy
US20240209393A1 (en) Synthetic aav vectors for repeated delivery of therapeutic genes
US20240254483A1 (en) Compositions and methods for modulating expression of frataxin (fxn)
WO1999011652A1 (en) Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
Weigel-Kelley et al. Recombinant human parvovirus B19 vectors
WO2024163683A2 (en) Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2023220040A1 (en) Erythroparvovirus with a modified capsid for gene therapy
TW202402329A (zh) Irak4調節劑於基因療法之用途(二)
US20010036929A1 (en) Xrcc3 is required for assembly of Rad51-complexes in vivo
WO2024015881A2 (en) Compositions, systems, and methods for targeted transcriptional activation
Wright In vivo myocardial gene transfer: Optimization and evaluation of gene transfer models and vectors
He Modifying xenogeneic immune recognition and engraftment by genetic engineering

Legal Events

Date Code Title Description
FZDE Dead